Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
44 hedge funds and large institutions have $80.6M invested in Avadel Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 9 closing their positions.
174% more call options, than puts
Call options by funds: $655K | Put options by funds: $239K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
44% more capital invested
Capital invested by funds: $55.9M → $80.6M (+$24.7M)
0.06% more ownership
Funds ownership: 51.79% → 51.85% (+0.06%)
2% less funds holding
Funds holding: 45 → 44 (-1)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GJL
Gendell Jeffrey L
|
+$926K |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$430K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$304K |
| 4 |
Millennium Management
New York
|
+$298K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$236K |
Top Sellers
AVDL Hedge Fund Activity: Q3 2019 in Review
44 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2019, worth a combined $80.6M — up 44% from $55.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AVDL and 8 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 9 added.
The largest buyer was Gendell Jeffrey L, opening a new position worth an estimated $926K. The largest seller was Brandes Investment Partners, cutting an estimated $1.51M.
- 44 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2019, down from 45 in Q2 2019.
- Funds reported $80.6M of Avadel Pharmaceuticals stock for Q3 2019, up 44% quarter-over-quarter.
- 8 funds opened new Avadel Pharmaceuticals positions in Q3 2019 and 9 closed out, a net change of -1 holder.
- The largest Avadel Pharmaceuticals buyer in Q3 2019 was Gendell Jeffrey L, an estimated $926K added.
- The largest Avadel Pharmaceuticals seller in Q3 2019 was Brandes Investment Partners, an estimated $1.51M sold.
Based on aggregated 13F filings for Q3 2019.